| Recruiting | Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated NCT06130787 | University Hospital, Clermont-Ferrand | N/A |
| Recruiting | Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML NCT06724536 | Carmen Fava | — |
| Unknown | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic NCT05154474 | Weprom | — |
| Recruiting | Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase NCT05143840 | Augusta University | Phase 2 |
| Recruiting | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL NCT04260022 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukem NCT03578367 | Novartis Pharmaceuticals | Phase 2 |
| Completed | The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) NCT02269267 | Medical College of Wisconsin | Phase 2 |
| Unknown | Unrelated Double Umbilical Cord Blood Units Transplantation NCT01015742 | Tehran University of Medical Sciences | Phase 2 / Phase 3 |
| Withdrawn | Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid NCT00732186 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical NCT01050946 | Medical College of Wisconsin | Phase 2 |
| Completed | Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healt NCT00759837 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Safety Assessment of a Multipeptide-gene Vaccine in CML NCT00455221 | Tehran University of Medical Sciences | Phase 1 |
| Terminated | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers NCT00539656 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gle NCT00538109 | King Faisal Specialist Hospital & Research Center | N/A |
| Unknown | Prospective Database for Chronic Myelogenous Leukemia NCT00538447 | King Faisal Specialist Hospital & Research Center | N/A |
| Terminated | Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Bl NCT00449761 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0 NCT00406393 | Medical College of Wisconsin | Phase 3 |
| Terminated | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor NCT00393380 | The Emmes Company, LLC | Phase 2 |
| Terminated | Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatin NCT00320190 | Bristol-Myers Squibb | Phase 2 |
| Completed | Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to NCT00264160 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Terminated | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation NCT00306332 | Radboud University Medical Center | Phase 3 |
| Completed | A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib NCT00298987 | Bristol-Myers Squibb | Phase 2 |
| Completed | Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malign NCT00246662 | Sunesis Pharmaceuticals | Phase 1 |
| Completed | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive NCT00763763 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | Post Transplant Donor Lymphocyte Infusion NCT00167180 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukem NCT00050531 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Randomized Double Cord Blood Transplant Study NCT00067002 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ NCT00058747 | Agenus Inc. | Phase 2 |
| Completed | Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia NCT00040105 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Stem Cell Transplant for Hematological Malignancy NCT00176930 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) NCT00034684 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase NCT00027144 | University of Connecticut | Phase 1 |
| Completed | Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia NCT00167167 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies NCT00186342 | Stanford University | N/A |